Amgen: First to Market, First to Set Price?

Amgen (AMGN) said it had applied for approval for a new type of cholesterol drug, making it the leader in the race to get to market first. UBS analyst Matthew Rhoden explains why Amgen’s filing is a big deal: We are maintaining our Buy rating on Amgen shares (and Neutral on Regeneron (REGN)) following Amgen’s [...]